Tinea Pedis Treatment Market
Tinea Pedis Treatment Market by Disease Indication, Route of Administration, Distribution Channel, Drug Class & Region - Forecast 2022 – 2032
Will Providing Cost-Effective Anti-Fungal Drugs in Hospital Pharmacies Generate Maximum Profits for Tinea Pedis Drug Manufacturers? Explore FMI's Latest Study to Know More!
Tinea Pedis Treatment Market Outlook (2022-2032)
[286 Pages Report] The global tinea pedis treatment market is expected to reach US$ 1.35 Bn in 2022, and further expand at a CAGR rate of 5.2% to surpass ~US$ 2.24 Bn by the end of 2032. In terms of disease indication, the interdigital tinea pedis treatment market is expected to lead with a share of about 68.3% in 2022.
|
Attributes |
Key Insights |
|
Tinea Pedis Treatment Market Value 2021 |
US$ 1.29 Bn |
|
Estimated Market Value 2022 |
US$ 1.35 Bn |
|
Projected Market Value 2032 |
US$ 2.24 Bn |
|
CAGR 2022-2032 |
5.2% |
|
Market Share of Top 5 Countries |
62.1% |
One of the most common types of tinea infection is tinea pedis, alternatively called athlete foot. The main causative agents of tinea pedis include fungal spores found in bathrooms, swimming pools, and other wet places. Also, fewer fatty acids produced by the skin (a natural antifungal agent), wearing socks for an extended period, wearing the same pair of shoes, excessive perspiration, immunodeficiency, lymphedema, and other factors.
As per a study by NCBI in 2021, dermatophyte infections of the toe clefts may afflict 10% of the entire population. Trichophyton mentagrophytes and microsporum canis are becoming more common in China, according to a dermatology clinic study. Of the patients, 27% were found to have tinea pedis. The prevalence of tinea pedis in the U.S. is 12-18%.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Sales Analysis of Tinea Pedis Treatment Market from 2017 to 2021 Vs Market Outlook for 2022 to 2032
As per Future Market Insights (FMI), the tinea pedis treatment market was approximately 8.9% of the overall ~US$ 14.5 Bn global anti-fungal drugs market in 2021. Sales in tinea pedis treatment market held a global market value of US$ 1.29 Bn in 2021 while growing at a CAR of nearly 4.2% from 2012 till 2021.
For the past few decades, the increased prevalence of infectious diseases across the globe due to the massive change in ecosystems and animal infections has led to the emergence of novel fungal infections. Antifungal drug prophylaxis and long-term therapeutic use in high-risk patients have facilitated the establishment of (multi) drug resistance.
In a study conducted by NCBI in the journal of ‘unicellular biology and human disease’ in June 2020, around 1.7 million people die yearly from over 150 million severe fungal infections. Tinea pedis is a very common and persistent infection in European nations. Fungal infection is found in people who participate in sports like swimming, running, and other activities.
In the U.K., tinea pedis affects 15% of people, as per the study. As a result, numerous pharma companies are investing in innovating effective antifungal drugs in the market. Increasing research and development activities is also catering to the needs of new treatment options for fungal infections and diseases.
Another study by NCBI in 2017 suggests that prevalence of tinea pedis is high in age groups of people over 60 years. Owing to the aforementioned factors, the global tinea pedis treatment market is expected to grow at a CAGR of 5.2% during the forecast period from 2022 to 2032.
What are the Key Opportunities for the Tinea Pedis Drug Manufacturers?
Rising Research Activities to Develop Anti-Fungal Drugs to Aid the Growth
As per the reports of the Indian Journal of Medical Research in 2020, the growing prevalence of fungal infections, especially in sub-tropical regions due to their temperature adaptation, causes several deaths yearly.
The market for tinea pedis drugs is set to present an opportunistic outlook, owing to the rising global awareness and advertisement of new speciality drugs for such infections. The U.S. Food and Drug Administration (FDA) is also supporting the development of such drugs.
For instance, in January 2021, the Global Anti-Microbial Resistance R&D Hub stated that 1,047 fungal R&D projects had received a total of USD 362 million in funding, most of which has gone towards human-related research studies.
The growth will further be propelled by the new adaptation of lifestyle like increased urbanization, increased usage of athletic and fitness facilities, rising obesity rates, and a rise in immunocompromised patients, providing further growth opportunities to the drug manufacturers within the tinea pedis treatment market.
Sabyasachi Ghosh
Principal Consultant
Talk to Analyst
Find your sweet spots for generating winning opportunities in this market.
What are the Factors Restraining Demand for Tinea Pedis Drugs?
Although various treatment options and antifungal drugs on the market claim improvement but there have been multiple re-occurrences of tinea pedis infection even after prolonged treatment.
Hence, the increasing concerns of the FDA and the stringent guidelines for the approval and launching of such products may pose as a deterring factor towards the growth of the market.
Another factor restraining the growth is the limited awareness of fungal infections in underdeveloped countries. These, along with patients’ non-adherence to the treatment regime, low treatment seeking rates, counterfeit and off-label drug use, high-cost constraint and lack of resources, might impede the growth in tinea pedis treatment market.
Country-wise Insights
Why is the U.S. Considered a Highly Lucrative Tinea Pedis Treatment Market?
Rising Prevalence of Skin Infections Among Millennials to Spur the Growth
The U.S. dominated the North America tinea pedis treatment market with a total share of about 96.2% in 2021 and is expected to gain traction over the forecast period. This is due to the high prevalence of skin infections, especially among teenagers. Further, rising number of product launches for the treatment will also boost the market.
What is the Outlook for China Tinea Pedis Treatment Market?
China Tinea Pedis Treatment to Gain Impetus Amid Rising Cases of Plantar Tinea Pedis
As per FMI, China is expected to account for 15.3% of the global share and is expected to witness growth at a CAGR 6.3% over the forecast period. Increasing number of patients with athlete’s foot, enhanced healthcare infrastructure and growing number of retail pharmacy chains will bolster the growth of tinea pedis treatment market.
Additionally, increasing prevalence of plantar tinea pedis, also known as moccasin foot, occurs on the side of the foot, will drive the demand in the market. Hence, several leading players are eyeing China tinea pedis treatment market to capitalize on growing need for anti-fungal drugs and serums.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Category-wise Insights
Which Disease Indication is Driving the Tinea Pedis Treatment Market?
Nearly 7 Out of 10 Sales to Come from Interdigital Tinea Pedis
Interdigital tinea pedis, by indication, is expected to hold a market share of 68.3% in the global market in 2022 and is expected to grow at a CAGR of 5.0% during the forecast period. Interdigital tinea pedis is the most common infection (between 4th and 5th toe space). Hence, key companies are investing in research for new treatment trends and effective drugs.
Further, in terms of route of administration, the topical segment is estimated to account for 79.3% of market share globally in 2022 and is forecasted to grow at a CAGR of 5.0%. Topical form administration is considered to be the most adequate and widely used route for drug administration because of its targeted therapy and fewer side effects.
Which is the Leading Distribution Channel in the Tinea Pedis Treatment Market?
Demand to Remain High for Antifungal Drugs within Hospital Pharmacies
Hospital pharmacies will account for a market share of nearly 35% in the global market in 2022. Hospital pharmacies are expected to dominate the market as it is the most preferred location for patients for the purchase of antifungal drugs.
Meanwhile, antifungal drug class is expected to show a growth rate of 4.8% in the forecast period. Antifungals are considered the most commonly used drug class owing to their effective actions and less possibility of adverse effects.
Competitive Landscape
As per the study, the tinea pedis treatment market is highly fragmented. In order to meet the demand and expand their customer base, key companies are implementing inorganic and organic strategies such as high R&D expenses for clinical trials and new product launches.
For Instance:
- In June 2022, Kerasal announced the launch of Athlete’s Foot Invisible Powder spray, Athlete’s Foot Silky Clear Gel and Athlete’s Foot Rapid Symptom Relief Medicated Soak a 5-in-1 benefit product pipeline for not only treating athlete’s foot but also improve the aesthetic appearance of skin.
- On January, 2021, DermBiont an early stage bio pharmaceutical company announced positive results for their phase 2 clinical trial on their latest development DBI-001 which is a live bacterial product. It claims to show benefit towards treatment of tinea pedis and atopic dermatitis.
Report Scope as per Tinea Pedis Treatment Market Analysis
|
Attribute |
Details |
|
Estimated Market Value 2022 |
US$ 1.35 Bn |
|
Projected Market Value 2032 |
US$ 2.24 Bn |
|
CAGR 2022-2032 |
5.2% |
|
Forecast Period |
2022-2032 |
|
Historical Data Available for |
2012-2021 |
|
Market Analysis |
US$ Bn for Value |
|
Key Regions Covered |
North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa |
|
Key Countries Covered |
U.S., Canada, Brazil, Mexico, Argentina, U.K., Germany, Italy, Russia, Spain, France, BENELUX, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC, and South Africa |
|
Key Market Segments Covered |
Disease Indication , Route of Administration , Distribution Channel, Drug Class and Region |
|
Key Companies Profiled |
|
Key Market Segments Covered in Tinea Pedis Treatment Industry Research
By Disease Indication:
- Interdigital Tinea Pedis
- Plantar Tinea Pedis
- Vesicular Tinea Pedis
By Route of Administration:
- Topical
- Gel
- Cream
- Spray
- Lotion
- Powder
- Oral
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Online Pharmacies
By Drug Class:
- Antifungals
- Combination
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa (MEA)
Frequently Asked Questions
How much is the tinea pedis treatment market worth in 2021?
The global tinea pedis treatment market is worth US$ 1.29 Bn in 2021, and is set to expand 1.7 X over the next ten years.
What is the sales forecast for tinea pedis treatment market through 2032?
The tinea pedis treatment market is expected to reach US$ 2.24 Bn by the end of 2032, with sales revenue expected to register 5.2% CAGR.
What are the key trends shaping the tinea pedis treatment industry?
The expanding research and development in the tinea pedis treatment, rising awareness among consumers about fungal infections, immense advertising, rise in number of immunocompromised patients and rise in the geriatric population, are some of the key trends in this market.
Which are the top 5 countries driving demand for tinea pedis treatment?
U.S, China, Brazil, Japan and India are the top 5 countries and are expected to drive demand for the tinea pedis treatment industry.
What is the North American market outlook for tinea pedis treatment?
North America is one of the key markets for tinea pedis treatment, with the U.S. accounting 96.2 % of the North American tinea pedis treatment market in the year 2021.
At what percentage is the demand for tinea pedis treatment expected to register growth in Europe?
Demand for tinea pedis treatment in Europe is expected to register a growth at 5.2% CAGR over the next ten years.
Which countries are the key producers of tinea pedis treatment?
The U.S., China and Brazil are the key producers of tinea pedis treatment drugs.
Table of Content
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply-Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Disease Indication Innovation / Development Trends 4. Key Inclusions 4.1. Key Regulations 4.2. Key Strategies Adopted by Manufacturer 4.3. PESTLE Analysis 4.4. Porter’s Analysis 4.5. Product Adoption Analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global GDP Outlook 5.1.2. Global Healthcare Spending Outlook 5.2. Forecast Factors - Relevance & Impact 5.2.1. Historical Growth of Key Players 5.2.2. Disease Indication Pipeline 5.2.3. New Product Launches 5.2.4. R&D Expenditure by Key Players 5.2.5. Rising Prevalence of Infectious Diseases 5.2.6. Adoption Rate 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. COVID-18 Crisis Analysis 6.1. COVID-18 and Impact Analysis 6.1.1. By Disease Indication 6.1.2. By Route of Administration 6.1.3. By Distribution Channel 6.1.4. By Drug Class 6.1.5. By Region 6.2. 1920 Market Scenario 7. Global Tinea Pedis Treatment Market Demand (in Value or Size in US$ Mn) Analysis 2012-2021 and Forecast, 2022-2032 7.1. Historical Market Value (US$ Mn) Analysis, 2012-2021 7.2. Current and Future Market Value (US$ Mn) Projections, 2022-2032 7.2.1. Y-o-Y Growth Trend Analysis 7.2.2. Absolute $ Opportunity Analysis 8. Global Tinea Pedis Treatment Market Analysis 2012-2021 and Forecast 2022-2032, By Disease Indication 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Mn) Analysis by Disease Indication, 2012-2021 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Disease Indication, 2022-2032 8.3.1. Interdigital Tinea Pedis 8.3.2. Plantar Tinea Pedis 8.3.3. Vesicular Tinea Pedis 8.4. Market Attractiveness Analysis by Disease Indication 9. Global Tinea Pedis Treatment Market Analysis 2012-2021 and Forecast 2022-2032, By Route of Administration 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Mn) Analysis by Route of Administration, 2012-2021 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Route of Administration, 2022-2032 9.3.1. Topical 9.3.1.1. Gel 9.3.1.2. Cream 9.3.1.3. Spray 9.3.1.4. Lotion 9.3.1.5. Powder 9.3.2. Oral 9.4. Market Attractiveness Analysis by Route of Administration 10. Global Tinea Pedis Treatment Market Analysis 2012-2021 and Forecast 2022-2032, by Distribution Channel 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Mn) Analysis by Distribution Channel, 2012-2021 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Distribution Channel, 2022-2032 10.3.1. Hospital Pharmacies 10.3.2. Retail Pharmacies 10.3.3. Drug Stores 10.3.4. Online Pharmacies 10.4. Market Attractiveness Analysis by Distribution Channel 11. Global Tinea Pedis Treatment Market Analysis 2012-2021 and Forecast 2022-2032, by Drug Class 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Mn) Analysis by Drug Class, 2012-2021 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Drug Class, 2022-2032 11.3.1. Hospital Pharmacies 11.3.2. Retail Pharmacies 11.3.3. Drug Stores 11.3.4. Online Pharmacies 11.4. Market Attractiveness Analysis by Drug Class 12. Global Tinea Pedis Treatment Market Analysis 2012-2021 and Forecast 2022-2032, by Region 12.1. Introduction 12.2. Historical Market Size (US$ Mn) Analysis by Region, 2012-2021 12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Region, 2022-2032 12.3.1. North America 12.3.2. Latin America 12.3.3. Europe 12.3.4. South Asia 12.3.5. East Asia 12.3.6. Oceania 12.3.7. Middle East and Africa (MEA) 12.4. Market Attractiveness Analysis by Region 13. North America Tinea Pedis Treatment Market Analysis 2012-2021 and Forecast 2022-2032 13.1. Introduction 13.2. Historical Market Size (US$ Mn) and Volume (Units) Trend Analysis by Market Taxonomy, 2012-2021 13.3. Current and Future Market Size (US$ Mn) and Volume (Units) Forecast By Market Taxonomy, 2022-2032 13.3.1. By Country 13.3.1.1. U.S. 13.3.1.2. Canada 13.3.2. By Disease Indication 13.3.3. By Route of Administration 13.3.4. By Distribution Channel 13.3.5. By Drug Class 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Disease Indication 13.4.3. By Route of Administration 13.4.4. By Distribution Channel 13.4.5. By Drug Class 13.5. Key Market Participants - Intensity Mapping 13.6. Drivers and Restraints - Impact Analysis 13.7. Country Level Analysis & Forecast 13.7.1. U.S. Tinea Pedis Treatment Market 13.7.1.1. Introduction 13.7.1.2. Market Analysis and Forecast by Market Taxonomy 13.7.1.2.1. By Disease Indication 13.7.1.2.2. By Route of Administration 13.7.1.2.3. By Distribution Channel 13.7.1.2.4. By Drug Class 13.7.2. Canada Tinea Pedis Treatment Market 13.7.2.1. Introduction 13.7.2.2. Market Analysis and Forecast by Market Taxonomy 13.7.2.2.1. By Disease Indication 13.7.2.2.2. By Route of Administration 13.7.2.2.3. By Distribution Channel 13.7.2.2.4. By Drug Class 14. Latin America Tinea Pedis Treatment Market Analysis 2012-2021 and Forecast 2022-2032 14.1. Introduction 14.2. Historical Market Size (US$ Mn) and Volume (Units) Trend Analysis by Market Taxonomy, 2012-2021 14.3. Current and Future Market Size (US$ Mn) and Volume (Units) Forecast By Market Taxonomy, 2022-2032 14.3.1. By Country 14.3.1.1. Brazil 14.3.1.2. Mexico 14.3.1.3. Argentina 14.3.1.4. Rest of Latin America 14.3.2. By Disease Indication 14.3.3. By Route of Administration 14.3.4. By Distribution Channel 14.3.5. By Drug Class 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Disease Indication 14.4.3. By Route of Administration 14.4.4. By Distribution Channel 14.4.5. By Drug Class 14.5. Key Market Participants - Intensity Mapping 14.6. Drivers and Restraints - Impact Analysis 14.7. Country Level Analysis & Forecast 14.7.1. Brazil Tinea Pedis Treatment Market 14.7.1.1. Introduction 14.7.1.2. Market Analysis and Forecast by Market Taxonomy 14.7.1.2.1. By Disease Indication 14.7.1.2.2. By Route of Administration 14.7.1.2.3. By Distribution Channel 14.7.1.2.4. By Drug Class 14.7.2. Mexico Tinea Pedis Treatment Market 14.7.2.1. Introduction 14.7.2.2. Market Analysis and Forecast by Market Taxonomy 14.7.2.2.1. By Disease Indication 14.7.2.2.2. By Route of Administration 14.7.2.2.3. By Distribution Channel 14.7.2.2.4. By Drug Class 14.7.3. Argentina Tinea Pedis Treatment Market 14.7.3.1. Introduction 14.7.3.2. Market Analysis and Forecast by Market Taxonomy 14.7.3.2.1. By Disease Indication 14.7.3.2.2. By Route of Administration 14.7.3.2.3. By Distribution Channel 14.7.3.2.4. By Drug Class 15. Europe Tinea Pedis Treatment Market Analysis 2012-2021 and Forecast 2022-2032 15.1. Introduction 15.2. Historical Market Size (US$ Mn) and Volume (Units) Trend Analysis by Market Taxonomy, 2012-2021 15.3. Current and Future Market Size (US$ Mn) and Volume (Units) Forecast By Market Taxonomy, 2022-2032 15.3.1. By Country 15.3.1.1. Germany 15.3.1.2. Italy 15.3.1.3. France 15.3.1.4. U.K. 15.3.1.5. Spain 15.3.1.6. BENELUX 15.3.1.7. Russia 15.3.1.8. Nordic Countries 15.3.1.9. Rest of Europe 15.3.2. By Disease Indication 15.3.3. By Route of Administration 15.3.4. By Distribution Channel 15.3.5. By Drug Class 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Disease Indication 15.4.3. By Route of Administration 15.4.4. By Distribution Channel 15.4.5. By Drug Class 15.5. Key Market Participants - Intensity Mapping 15.6. Drivers and Restraints - Impact Analysis 15.7. Country Level Analysis & Forecast 15.7.1. Germany Tinea Pedis Treatment Market 15.7.1.1. Introduction 15.7.1.2. Market Analysis and Forecast by Market Taxonomy 15.7.1.2.1. By Disease Indication 15.7.1.2.2. By Route of Administration 15.7.1.2.3. By Distribution Channel 15.7.1.2.4. By Drug Class 15.7.2. France Tinea Pedis Treatment Market 15.7.2.1. Introduction 15.7.2.2. Market Analysis and Forecast by Market Taxonomy 15.7.2.2.1. By Disease Indication 15.7.2.2.2. By Route of Administration 15.7.2.2.3. By Distribution Channel 15.7.2.2.4. By Drug Class 15.7.3. Italy Tinea Pedis Treatment Market 15.7.3.1. Introduction 15.7.3.2. Market Analysis and Forecast by Market Taxonomy 15.7.3.2.1. By Disease Indication 15.7.3.2.2. By Route of Administration 15.7.3.2.3. By Distribution Channel 15.7.3.2.4. By Drug Class 15.7.4. Spain Tinea Pedis Treatment Market 15.7.4.1. Introduction 15.7.4.2. Market Analysis and Forecast by Market Taxonomy 15.7.4.2.1. By Disease Indication 15.7.4.2.2. By Route of Administration 15.7.4.2.3. By Distribution Channel 15.7.4.2.4. By Drug Class 15.7.5. U.K. Tinea Pedis Treatment Market 15.7.5.1. Introduction 15.7.5.2. Market Analysis and Forecast by Market Taxonomy 15.7.5.2.1. By Disease Indication 15.7.5.2.2. By Route of Administration 15.7.5.2.3. By Distribution Channel 15.7.5.2.4. By Drug Class 15.7.6. BENELUX Union Tinea Pedis Treatment Market 15.7.6.1. Introduction 15.7.6.2. Market Analysis and Forecast by Market Taxonomy 15.7.6.2.1. By Disease Indication 15.7.6.2.2. By Route of Administration 15.7.6.2.3. By Distribution Channel 15.7.6.2.4. By Drug Class 15.7.7. Russia Tinea Pedis Treatment Market 15.7.7.1. Introduction 15.7.7.2. Market Analysis and Forecast by Market Taxonomy 15.7.7.2.1. By Disease Indication 15.7.7.2.2. By Route of Administration 15.7.7.2.3. By Distribution Channel 15.7.7.2.4. By Drug Class 15.7.8. Nordic Countries Tinea Pedis Treatment Market 15.7.8.1. Introduction 15.7.8.2. Market Analysis and Forecast by Market Taxonomy 15.7.8.2.1. By Disease Indication 15.7.8.2.2. By Route of Administration 15.7.8.2.3. By Distribution Channel 15.7.8.2.4. By Drug Class 16. South Asia Tinea Pedis Treatment Market Analysis 2012-2021 and Forecast 2022-2032 16.1. Introduction 16.2. Historical Market Size (US$ Mn) and Volume (Units) Trend Analysis by Market Taxonomy, 2012-2021 16.3. Current and Future Market Size (US$ Mn) and Volume (Units) Forecast By Market Taxonomy, 2022-2032 16.3.1. By Country 16.3.1.1. India 16.3.1.2. Thailand 16.3.1.3. Indonesia 16.3.1.4. Malaysia 16.3.1.5. Rest of South Asia 16.3.2. By Disease Indication 16.3.3. By Route of Administration 16.3.4. By Distribution Channel 16.3.5. By Drug Class 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Disease Indication 16.4.3. By Route of Administration 16.4.4. By Distribution Channel 16.4.5. By Drug Class 16.5. Key Market Participants - Intensity Mapping 16.6. Drivers and Restraints - Impact Analysis 16.7. Country Level Analysis & Forecast 16.7.1. India Tinea Pedis Treatment Market 16.7.1.1. Introduction 16.7.1.2. Market Analysis and Forecast by Market Taxonomy 16.7.1.2.1. By Disease Indication Disease Indication 16.7.1.2.2. By Route of Administration 16.7.1.2.3. By Distribution Channel 16.7.1.2.4. By Drug Class 16.7.2. Indonesia Tinea Pedis Treatment Market 16.7.2.1. Introduction 16.7.2.2. Market Analysis and Forecast by Market Taxonomy 16.7.2.2.1. By Disease Indication Disease Indication 16.7.2.2.2. By Route of Administration 16.7.2.2.3. By Distribution Channel 16.7.2.2.4. By Drug Class 16.7.3. Malaysia Tinea Pedis Treatment Market 16.7.3.1. Introduction 16.7.3.2. Market Analysis and Forecast by Market Taxonomy 16.7.3.2.1. By Disease Indication Disease Indication 16.7.3.2.2. By Route of Administration 16.7.3.2.3. By Distribution Channel 16.7.3.2.4. By Drug Class 16.7.4. Thailand Tinea Pedis Treatment Market 16.7.4.1. Introduction 16.7.4.2. Market Analysis and Forecast by Market Taxonomy 16.7.4.2.1. By Disease Indication Disease Indication 16.7.4.2.2. By Route of Administration 16.7.4.2.3. By Distribution Channel 16.7.4.2.4. By Drug Class 17. East Asia Tinea Pedis Treatment Market Analysis 2012-2021 and Forecast 2022-2032 17.1. Introduction 17.2. Historical Market Size (US$ Mn) and Volume (Units) Trend Analysis by Market Taxonomy, 2012-2021 17.3. Current and Future Market Size (US$ Mn) and Volume (Units) Forecast By Market Taxonomy, 2022-2032 17.3.1. By Country 17.3.1.1. China 17.3.1.2. Japan 17.3.1.3. South Korea 17.3.2. By Disease Indication 17.3.3. By Route of Administration 17.3.4. By Distribution Channel 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Disease Indication 17.4.3. By Route of Administration 17.4.4. By Distribution Channel 17.4.5. By Drug Class 17.5. Key Market Participants - Intensity Mapping 17.6. Drivers and Restraints - Impact Analysis 17.7. Country Level Analysis & Forecast 17.7.1. China Tinea Pedis Treatment Market 17.7.1.1. Introduction 17.7.1.2. Market Analysis and Forecast by Market Taxonomy 17.7.1.2.1. By Disease Indication 17.7.1.2.2. By Route of Administration 17.7.1.2.3. By Distribution Channel 17.7.1.2.4. By Drug Class 17.7.2. Japan Tinea Pedis Treatment Market 17.7.2.1. Introduction 17.7.2.2. Market Analysis and Forecast by Market Taxonomy 17.7.2.2.1. By Disease Indication 17.7.2.2.2. By Route of Administration 17.7.2.2.3. By Distribution Channel 17.7.2.2.4. By Drug Class 17.7.3. South Korea Tinea Pedis Treatment Market 17.7.3.1. Introduction 17.7.3.2. Market Analysis and Forecast by Market Taxonomy 17.7.3.2.1. By Disease Indication 17.7.3.2.2. By Route of Administration 17.7.3.2.3. By Distribution Channel 17.7.3.2.4. By Drug Class 18. Oceania Tinea Pedis Treatment Market Analysis 2012-2021 and Forecast 2022-2032 18.1. Introduction 18.2. Historical Market Size (US$ Mn) and Volume (Units) Trend Analysis by Market Taxonomy, 2012-2021 18.3. Current and Future Market Size (US$ Mn) and Volume (Units) Forecast By Market Taxonomy, 2022-2032 18.3.1. By Country 18.3.1.1. Australia 18.3.1.2. New Zealand 18.3.2. By Disease Indication 18.3.3. By Route of Administration 18.3.4. By Distribution Channel 18.3.5. By Drug Class 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Disease Indication 18.4.3. By Route of Administration 18.4.4. By Distribution Channel 18.4.5. By Drug Class 18.5. Key Market Participants - Intensity Mapping 18.6. Drivers and Restraints - Impact Analysis 18.7. Country Level Analysis & Forecast 18.7.1. Australia Tinea Pedis Treatment Market 18.7.1.1. Introduction 18.7.1.2. Market Analysis and Forecast by Market Taxonomy 18.7.1.2.1. By Disease Indication 18.7.1.2.2. By Route of Administration 18.7.1.2.3. By Distribution Channel 18.7.1.2.4. By Drug Class 18.7.2. New Zealand Tinea Pedis Treatment Market 18.7.2.1. Introduction 18.7.2.2. Market Analysis and Forecast by Market Taxonomy 18.7.2.2.1. By Disease Indication 18.7.2.2.2. By Route of Administration 18.7.2.2.3. By Distribution Channel 18.7.2.2.4. By Drug Class 19. Middle East and Africa (MEA) Tinea Pedis Treatment Market Analysis 2012-2021 and Forecast 2022-2032 19.1. Introduction 19.2. Historical Market Size (US$ Mn) and Volume (Units) Trend Analysis by Market Taxonomy, 2012-2021 19.3. Current and Future Market Size (US$ Mn) and Volume (Units) Forecast By Market Taxonomy, 2022-2032 19.3.1. By Country 19.3.1.1. GCC Countries 19.3.1.2. Turkey 19.3.1.3. Israel 19.3.1.4. North Africa 19.3.1.5. South Africa 19.3.1.6. Rest of Middle East and Africa 19.3.2. By Disease Indication 19.3.3. By Route of Administration 19.3.4. By Distribution Channel 19.3.5. By Drug Class 19.4. Market Attractiveness Analysis 19.4.1. By Country 19.4.2. By Disease Indication 19.4.3. By Route of Administration 19.4.4. By Distribution Channel 19.4.5. By Drug Class 19.5. Key Market Participants - Intensity Mapping 19.6. Drivers and Restraints - Impact Analysis 19.7. Country Level Analysis & Forecast 19.7.1. GCC Countries Tinea Pedis Treatment Market 19.7.1.1. Introduction 19.7.1.2. Market Analysis and Forecast by Market Taxonomy 19.7.1.2.1. By Disease Indication 19.7.1.2.2. By Route of Administration 19.7.1.2.3. By Distribution Channel 19.7.1.2.4. By Drug Class 19.7.2. Israel Tinea Pedis Treatment Market 19.7.2.1. Introduction 19.7.2.2. Market Analysis and Forecast by Market Taxonomy 19.7.2.2.1. By Disease Indication 19.7.2.2.2. By Route of Administration 19.7.2.2.3. By Distribution Channel 19.7.2.2.4. By Drug Class 19.7.3. Turkey Tinea Pedis Treatment Market 19.7.3.1. Introduction 19.7.3.2. Market Analysis and Forecast by Market Taxonomy 19.7.3.2.1. By Disease Indication 19.7.3.2.2. By Route of Administration 19.7.3.2.3. By Distribution Channel 19.7.3.2.4. By Drug Class 19.7.4. South Africa Tinea Pedis Treatment Market 19.7.4.1. Introduction 19.7.4.2. Market Analysis and Forecast by Market Taxonomy 19.7.4.2.1. By Disease Indication 19.7.4.2.2. By Route of Administration 19.7.4.2.3. By Distribution Channel 19.7.4.2.4. By Drug Class 19.7.5. North Africa Tinea Pedis Treatment Market 19.7.5.1. Introduction 19.7.5.2. Market Analysis and Forecast by Market Taxonomy 19.7.5.2.1. By Disease Indication 19.7.5.2.2. By Route of Administration 19.7.5.2.3. By Distribution Channel 19.7.5.2.4. By Drug Class 20. Market Structure Analysis 20.1. Market Analysis by Tier of Companies 20.2. Market Share Analysis of Top Players 20.3. Market Presence Analysis 20.3.1. By Regional footprint of Players 20.3.2. Device footprint by Players 20.3.3. Channel Foot Print by Players 21. Competition Analysis 21.1. Competition Dashboard 21.2. Competition Benchmarking 21.3. Competition Deep Dive 21.3.1. STERIS 21.3.1.1. Overview & Key financials 21.3.1.2. Disease Indication Portfolio 21.3.1.3. Key Financials 21.3.1.4. Sales Footprint 21.3.1.5. Analysis Commentary 21.3.1.6. Strategy Overview 21.3.1.7. SWOT Analysis 21.3.2. Perrigo Company Plc. 21.3.2.1. Overview & Key financials 21.3.2.2. Disease Indication Portfolio 21.3.2.3. Key Financials 21.3.2.4. Sales Footprint 21.3.2.5. Analysis Commentary 21.3.2.6. Strategy Overview 21.3.2.7. SWOT Analysis 21.3.3. Novartis AG 21.3.3.1. Overview & Key financials 21.3.3.2. Disease Indication Portfolio 21.3.3.3. Key Financials 21.3.3.4. Sales Footprint 21.3.3.5. Analysis Commentary 21.3.3.6. Strategy Overview 21.3.3.7. SWOT Analysis 21.3.4. Valeant Pharmaceuticals International 21.3.4.1. Overview & Key financials 21.3.4.2. Disease Indication Portfolio 21.3.4.3. Key Financials 21.3.4.4. Sales Footprint 21.3.4.5. Analysis Commentary 21.3.4.6. Strategy Overview 21.3.4.7. SWOT Analysis 21.3.5. GlaxoSmithKline plc 21.3.5.1. Overview & Key financials 21.3.5.2. Disease Indication Portfolio 21.3.5.3. Key Financials 21.3.5.4. Sales Footprint 21.3.5.5. Analysis Commentary 21.3.5.6. Strategy Overview 21.3.5.7. SWOT Analysis 21.3.6. Bayer AG 21.3.6.1. Overview & Key financials 21.3.6.2. Disease Indication Portfolio 21.3.6.3. Key Financials 21.3.6.4. Sales Footprint 21.3.6.5. Analysis Commentary 21.3.6.6. Strategy Overview 21.3.6.7. SWOT Analysis 21.3.7. Teva Pharmaceuticals Industries Ltd. 21.3.7.1. Overview & Key financials 21.3.7.2. Disease Indication Portfolio 21.3.7.3. Key Financials 21.3.7.4. Sales Footprint 21.3.7.5. Analysis Commentary 21.3.7.6. Strategy Overview 21.3.7.7. SWOT Analysis 21.3.8. Mylan NV 21.3.8.1. Overview & Key financials 21.3.8.2. Disease Indication Portfolio 21.3.8.3. Key Financials 21.3.8.4. Sales Footprint 21.3.8.5. Analysis Commentary 21.3.8.6. Strategy Overview 21.3.8.7. SWOT Analysis 21.3.9. Glenmark Pharmaceutical Ltd 21.3.9.1. Overview & Key financials 21.3.9.2. Disease Indication Portfolio 21.3.9.3. Key Financials 21.3.9.4. Sales Footprint 21.3.9.5. Analysis Commentary 21.3.9.6. Strategy Overview 21.3.9.7. SWOT Analysis 21.3.10. Taro Pharmaceutical Industries Ltd. 21.3.10.1. Overview & Key financials 21.3.10.2. Disease Indication Portfolio 21.3.10.3. Key Financials 21.3.10.4. Sales Footprint 21.3.10.5. Analysis Commentary 21.3.10.6. Strategy Overview 21.3.10.7. SWOT Analysis 21.3.11. Camber Pharmaceuticals Inc 21.3.11.1. Overview & Key financials 21.3.11.2. Disease Indication Portfolio 21.3.11.3. Key Financials 21.3.11.4. Sales Footprint 21.3.11.5. Analysis Commentary 21.3.11.6. Strategy Overview 21.3.11.7. SWOT Analysis 21.3.12. Breckenridge Pharmaceutical, Inc 21.3.12.1. Overview & Key financials 21.3.12.2. Disease Indication Portfolio 21.3.12.3. Key Financials 21.3.12.4. Sales Footprint 21.3.12.5. Analysis Commentary 21.3.12.6. Strategy Overview 21.3.12.7. SWOT Analysis 21.3.13. Sebela Pharmaceuticals Inc. 21.3.13.1. Overview & Key financials 21.3.13.2. Disease Indication Portfolio 21.3.13.3. Key Financials 21.3.13.4. Sales Footprint 21.3.13.5. Analysis Commentary 21.3.13.6. Strategy Overview 21.3.13.7. SWOT Analysis 21.3.14. Blueberry Therapeutics Ltd 21.3.14.1. Overview & Key financials 21.3.14.2. Disease Indication Portfolio 21.3.14.3. Key Financials 21.3.14.4. Sales Footprint 21.3.14.5. Analysis Commentary 21.3.14.6. Strategy Overview 21.3.14.7. SWOT Analysis 21.3.15. AvKare Inc 21.3.15.1. Overview & Key financials 21.3.15.2. Disease Indication Portfolio 21.3.15.3. Key Financials 21.3.15.4. Sales Footprint 21.3.15.5. Analysis Commentary 21.3.15.6. Strategy Overview 21.3.15.7. SWOT Analysis 21.3.16. Aqua Pharmaceuticals LLC 21.3.16.1. Overview & Key financials 21.3.16.2. Disease Indication Portfolio 21.3.16.3. Key Financials 21.3.16.4. Sales Footprint 21.3.16.5. Analysis Commentary 21.3.16.6. Strategy Overview 21.3.16.7. SWOT Analysis 21.3.17. Exeltis USA, Inc. 21.3.17.1. Overview & Key financials 21.3.17.2. Disease Indication Portfolio 21.3.17.3. Key Financials 21.3.17.4. Sales Footprint 21.3.17.5. Analysis Commentary 21.3.17.6. Strategy Overview 21.3.17.7. SWOT Analysis 21.3.18. CorePharma, L.L.C 21.3.18.1. Overview & Key financials 21.3.18.2. Disease Indication Portfolio 21.3.18.3. Key Financials 21.3.18.4. Sales Footprint 21.3.18.5. Analysis Commentary 21.3.18.6. Strategy Overview 21.3.18.7. SWOT Analysis 21.3.19. McNEIL-PPC, Inc 21.3.19.1. Overview & Key financials 21.3.19.2. Disease Indication Portfolio 21.3.19.3. Key Financials 21.3.19.4. Sales Footprint 21.3.19.5. Analysis Commentary 21.3.19.6. Strategy Overview 21.3.19.7. SWOT Analysis 21.3.20. Aurobindo Pharma Ltd 21.3.20.1. Overview & Key financials 21.3.20.2. Disease Indication Portfolio 21.3.20.3. Key Financials 21.3.20.4. Sales Footprint 21.3.20.5. Analysis Commentary 21.3.20.6. Strategy Overview 21.3.20.7. SWOT Analysis 22. Assumptions and Acronyms Used 23. Research Methodolog
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 01: Global Tinea Pedis Treatment Size (US$ Bn) Analysis and Forecast 2022–2032, by Disease Indication Table 02: Global Tinea Pedis Treatment Size (US$ Bn) Analysis and Forecast 2022–2032, by Route of Administration Table 03: Global Tinea Pedis Treatment Size (US$ Bn) Analysis and Forecast 2022–2032, by Distribution Channel Table 04: Global Tinea Pedis Treatment Value (US$ Bn) Analysis- and Forecast 2022–2032, by Drug Class Table 05: North America Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Country Table 06: North America Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Disease Indication Table 07: North America Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Route of Administration Table 08: North America Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Distribution Channel Table 09: North America Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Drug Class Table 10: Latin America Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Country Table 11: Latin America Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Disease Indication Table 12: Latin America Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Route of Administration Table 13: Latin America Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Distribution Channel Table 14: Latin America Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Drug Class Table 15: Europe Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Country Table 16: Europe Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Disease Indication Table 17: Europe Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Route of Administration Table 18: Europe Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Distribution Channel Table 19: Europe Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Drug Class Table 20: South Asia Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Country Table 21: South Asia Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Disease Indication Table 22: South Asia Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Route of Administration Table 23: South Asia Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Distribution Channel Table 24: South Asia Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Drug Class Table 25: East Asia Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Country Table 26: East Asia Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Disease Indication Table 27: East Asia Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Route of Administration Table 28: East Asia Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Distribution Channel Table 29: East Asia Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Drug Class Table 30: Oceania Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Country Table 31: Oceania Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Disease Indication Table 32: Oceania Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Route of Administration Table 33: Oceania Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Distribution Channel Table 34: Oceania Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Drug Class Table 35: Middle East & Africa Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Country Table 36: Middle East & Africa Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Disease Indication Table 37: Middle East & Africa Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Route of Administration Table 38: Middle East & Africa Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Distribution Channel Table 39: Middle East & Africa Tinea Pedis Treatment Size Analysis 2017–2021 and Forecast 2022–2032, by Drug Class
Sabyasachi Ghosh
Principal Consultant
Talk to Analyst
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 01: Global Tinea Pedis Treatment Value Analysis (US$ Bn), 2014-2021 Figure 02: Global Tinea Pedis Treatment Value Forecast (US$ Bn), 2021-2032 Figure 03: Global Tinea Pedis Treatment Absolute $ Opportunity, 2021 - 2032 Figure 04: Global Tinea Pedis Treatment Share Analysis (%), by Disease Indication, 2022 & 2032 Figure 05: Global Tinea Pedis Treatment Y-o-Y Analysis (%), by Disease Indication, 2022-2032 Figure 06: Global Tinea Pedis Treatment Attractiveness Analysis by Disease Indication, 2022-2032 Figure 07: Global Tinea Pedis Treatment Share Analysis (%), by Route of Administration, 2022 & 2032 Figure 08: Global Tinea Pedis Treatment Y-o-Y Analysis (%), by Route of Administration, 2022-2032 Figure 09: Global Tinea Pedis Treatment Attractiveness Analysis by Route of Administration, 2022-2032 Figure 10: Global Tinea Pedis Treatment Share Analysis (%), by Distribution Channel, 2022 & 2032 Figure 11: Global Tinea Pedis Treatment Y-o-Y Analysis (%), by Distribution Channel, 2022-2032 Figure 12: Global Tinea Pedis Treatment Attractiveness Analysis by Distribution Channel, 2022-2032 Figure 13: Global Tinea Pedis Treatment Share Analysis (%), Drug Class, 2022 & 2032 Figure 14: Global Tinea Pedis Treatment Y-o-Y Analysis (%), Drug Class, 2022-2032 Figure 15: Global Tinea Pedis Treatment Attractiveness Analysis Drug Class, 2022-2032 Figure 16: North America Tinea Pedis Treatment Value Share by Disease Indication 2022 (E) Figure 17: North America Tinea Pedis Treatment Value Share by Route of Administration 2022 (E) Figure 18: North America Tinea Pedis Treatment Value Share by Distribution Channel 2022 (E) Figure 19: North America Tinea Pedis Treatment Value Share Drug Class 2022 (E) Figure 20: North America Tinea Pedis Treatment Value Share by Country 2022 (E) Figure 21: North America Tinea Pedis Treatment Historical Market Size (US$ Bn) Analysis, 2014–2021 Figure 22: North America Tinea Pedis Treatment Current and Future Market Size (US$ Bn), 2021-2032 & Y-o-Y Growth Trend Analysis Figure 23: North America Tinea Pedis Treatment Attractiveness Analysis by Disease Indication, 2022-2032 Figure 24: North America Tinea Pedis Treatment Attractiveness Analysis by Route of Administration, 2022-2032 Figure 25: North America Tinea Pedis Treatment Attractiveness Analysis by Distribution Channel, 2022-2032 Figure 26: North America Tinea Pedis Treatment Attractiveness Analysis Drug Class, 2022-2032 Figure 27: North America Tinea Pedis Treatment Attractiveness Analysis by Country, 2022-2032 Figure 28: U.S. Market Value Proportion Analysis, 2021 Figure 29: U.S. Tinea Pedis Treatment Share Analysis (%), by Disease Indication, 2021 & 2032 Figure 30: U.S. Tinea Pedis Treatment Share Analysis (%), by Route of Administration, 2021 & 2032 Figure 31: U.S. Tinea Pedis Treatment Share Analysis (%), by Distribution Channel, 2021 & 2032 Figure 32: U.S. Tinea Pedis Treatment Share Analysis (%), Drug Class, 2021 & 2032 Figure 33: Canada Market Value Proportion Analysis, 2021 Figure 34: Canada Tinea Pedis Treatment Share Analysis (%), by Disease Indication, 2021 & 2032 Figure 35: Canada Tinea Pedis Treatment Share Analysis (%), by Route of Administration, 2021 & 2032 Figure 36: Canada Tinea Pedis Treatment Share Analysis (%), by Distribution Channel, 2021 & 2032 Figure 37: Canada Tinea Pedis Treatment Share Analysis (%), Drug Class, 2021 & 2032 Figure 38: Latin America Tinea Pedis Treatment Value Share by Disease Indication 2022 (E) Figure 39: Latin America Tinea Pedis Treatment Value Share by Route of Administration 2022 (E) Figure 40: Latin America Tinea Pedis Treatment Value Share by Distribution Channel 2022 (E) Figure 41: Latin America Tinea Pedis Treatment Value Share Drug Class 2022 (E) Figure 42: Latin America Tinea Pedis Treatment Value Share by Country 2022 (E) Figure 43: Latin America Tinea Pedis Treatment Historical Market Size (US$ Bn) Analysis, 2014–2021 Figure 44: Latin America Tinea Pedis Treatment Current and Future Market Size (US$ Bn), 2021-2032 & Y-o-Y Growth Trend Analysis Figure 45: Latin America Tinea Pedis Treatment Attractiveness Analysis by Disease Indication, 2022-2032 Figure 46: Latin America Tinea Pedis Treatment Attractiveness Analysis by Route of Administration, 2022-2032 Figure 47: Latin America Tinea Pedis Treatment Attractiveness Analysis by Distribution Channel, 2022-2032 Figure 48: Latin America Tinea Pedis Treatment Attractiveness Analysis Drug Class, 2022-2032 Figure 49: Latin America Tinea Pedis Treatment Attractiveness Analysis by Country, 2022-2032 Figure 50: Brazil Market Value Proportion Analysis, 2021 Figure 51: Brazil Tinea Pedis Treatment Share Analysis (%), by Disease Indication, 2021 & 2032 Figure 52: Brazil Tinea Pedis Treatment Share Analysis (%), by Route of Administration, 2021 & 2032 Figure 53: Brazil Tinea Pedis Treatment Share Analysis (%), by Distribution Channel, 2021 & 2032 Figure 54: Brazil Tinea Pedis Treatment Share Analysis (%), Drug Class, 2021 & 2032 Figure 55: Mexico Market Value Proportion Analysis, 2021 Figure 56: Mexico Tinea Pedis Treatment Share Analysis (%), by Disease Indication, 2021 & 2032 Figure 57: Mexico Tinea Pedis Treatment Share Analysis (%), by Route of Administration, 2021 & 2032 Figure 58: Mexico Tinea Pedis Treatment Share Analysis (%), by Distribution Channel, 2021 & 2032 Figure 59: Mexico Tinea Pedis Treatment Share Analysis (%), Drug Class, 2021 & 2032 Figure 60: Argentina Market Value Proportion Analysis, 2021 Figure 61: Argentina Tinea Pedis Treatment Share Analysis (%), by Disease Indication, 2021 & 2032 Figure 62: Argentina Tinea Pedis Treatment Share Analysis (%), by Route of Administration, 2021 & 2032 Figure 63: Argentina Tinea Pedis Treatment Share Analysis (%), by Distribution Channel, 2021 & 2032 Figure 64: Argentina Tinea Pedis Treatment Share Analysis (%), Drug Class, 2021 & 2032 Figure 65: Europe Tinea Pedis Treatment Value Share by Disease Indication 2022 (E) Figure 66: Europe Tinea Pedis Treatment Value Share by Route of Administration 2022 (E) Figure 67: Europe Tinea Pedis Treatment Value Share by Distribution Channel 2022 (E) Figure 68: Europe Tinea Pedis Treatment Value Share Drug Class 2022 (E) Figure 69: Europe Tinea Pedis Treatment Value Share by Country 2022 (E) Figure 70: Europe Tinea Pedis Treatment Historical Market Size (US$ Bn) Analysis, 2014–2021 Figure 71: Europe Tinea Pedis Treatment Current and Future Market Size (US$ Bn), 2021-2032 & Y-o-Y Growth Trend Analysis Figure 72: Europe Tinea Pedis Treatment Attractiveness Analysis by Disease Indication, 2022-2032 Figure 73: Europe Tinea Pedis Treatment Attractiveness Analysis by Route of Administration, 2022-2032 Figure 74: Europe Tinea Pedis Treatment Attractiveness Analysis by Distribution Channel, 2022-2032 Figure 75: Europe Tinea Pedis Treatment Attractiveness Analysis Drug Class, 2022-2032 Figure 76: Europe Tinea Pedis Treatment Attractiveness Analysis by Country, 2022-2032 Figure 77: Italy Market Value Proportion Analysis, 2021 Figure 78: Italy Tinea Pedis Treatment Share Analysis (%), by Disease Indication, 2021 & 2032 Figure 79: Italy Tinea Pedis Treatment Share Analysis (%), by Route of Administration, 2021 & 2032 Figure 80: Italy Tinea Pedis Treatment Share Analysis (%), by Distribution Channel, 2021 & 2032 Figure 81: Italy Tinea Pedis Treatment Share Analysis (%), Drug Class, 2021 & 2032 Figure 82: Germany Market Value Proportion Analysis, 2021 Figure 83: Germany Tinea Pedis Treatment Share Analysis (%), by Disease Indication, 2021 & 2032 Figure 84: Germany Tinea Pedis Treatment Share Analysis (%), by Route of Administration, 2021 & 2032 Figure 85: Germany Tinea Pedis Treatment Share Analysis (%), by Distribution Channel, 2021 & 2032 Figure 86: Germany Tinea Pedis Treatment Share Analysis (%), Drug Class, 2021 & 2032 Figure 87: U.K. Market Value Proportion Analysis, 2021 Figure 88: U.K. Tinea Pedis Treatment Share Analysis (%), by Disease Indication, 2021 & 2032 Figure 89: U.K. Tinea Pedis Treatment Share Analysis (%), by Route of Administration, 2021 & 2032 Figure 90: U.K. Tinea Pedis Treatment Share Analysis (%), by Distribution Channel, 2021 & 2032 Figure 91: U.K. Tinea Pedis Treatment Share Analysis (%), Drug Class, 2021 & 2032 Figure 92: France Market Value Proportion Analysis, 2021 Figure 93: France Tinea Pedis Treatment Share Analysis (%), by Disease Indication, 2021 & 2032 Figure 94: France Tinea Pedis Treatment Share Analysis (%), by Route of Administration, 2021 & 2032 Figure 95: France Tinea Pedis Treatment Share Analysis (%), by Distribution Channel, 2021 & 2032 Figure 96: France Tinea Pedis Treatment Share Analysis (%), Drug Class, 2021 & 2032 Figure 97: Spain Market Value Proportion Analysis, 2021 Figure 98: Spain Tinea Pedis Treatment Share Analysis (%), by Disease Indication, 2021 & 2032 Figure 99: Spain Tinea Pedis Treatment Share Analysis (%), by Route of Administration, 2021 & 2032 Figure 100: Spain Tinea Pedis Treatment Share Analysis (%), by Distribution Channel, 2021 & 2032 Figure 101: Spain Tinea Pedis Treatment Share Analysis (%), Drug Class, 2021 & 2032 Figure 102: BENELUX Market Value Proportion Analysis, 2021 Figure 103: BENELUX Tinea Pedis Treatment Share Analysis (%), by Disease Indication, 2021 & 2032 Figure 104: BENELUX Tinea Pedis Treatment Share Analysis (%), by Route of Administration, 2021 & 2032 Figure 105: BENELUX Tinea Pedis Treatment Share Analysis (%), by Distribution Channel, 2021 & 2032 Figure 106: BENELUX Tinea Pedis Treatment Share Analysis (%), Drug Class, 2021 & 2032 Figure 107: Nordic Countries Market Value Proportion Analysis, 2021 Figure 108: Nordic Countries Tinea Pedis Treatment Share Analysis (%), by Disease Indication, 2021 & 2032 Figure 109: Nordic Countries Tinea Pedis Treatment Share Analysis (%), by Route of Administration, 2021 & 2032 Figure 110: Nordic Countries Tinea Pedis Treatment Share Analysis (%), by Distribution Channel, 2021 & 2032 Figure 111: Nordic Countries Tinea Pedis Treatment Share Analysis (%), Drug Class, 2021 & 2032 Figure 112: Russia Market Value Proportion Analysis, 2021 Figure 113: Russia Tinea Pedis Treatment Share Analysis (%), by Disease Indication, 2021 & 2032 Figure 114: Russia Tinea Pedis Treatment Share Analysis (%), by Route of Administration, 2021 & 2032 Figure 115: Russia Tinea Pedis Treatment Share Analysis (%), by Distribution Channel, 2021 & 2032 Figure 116: Russia Tinea Pedis Treatment Share Analysis (%), Drug Class, 2021 & 2032 Figure 117: South Asia Tinea Pedis Treatment Value Share by Disease Indication 2022 (E) Figure 118: South Asia Tinea Pedis Treatment Value Share by Route of Administration 2022 (E) Figure 119: South Asia Tinea Pedis Treatment Value Share by Distribution Channel 2022 (E) Figure 120: South Asia Tinea Pedis Treatment Value Share Drug Class 2022 (E) Figure 121: South Asia Tinea Pedis Treatment Value Share by Country 2022 (E) Figure 122: South Asia Tinea Pedis Treatment Historical Market Size (US$ Bn) Analysis, 2014–2021 Figure 123: South Asia Tinea Pedis Treatment Current and Future Market Size (US$ Bn), 2021-2032 & Y-o-Y Growth Trend Analysis Figure 124: South Asia Tinea Pedis Treatment Attractiveness Analysis by Disease Indication, 2022-2032 Figure 125: South Asia Tinea Pedis Treatment Attractiveness Analysis by Route of Administration, 2022-2032 Figure 126: South Asia Tinea Pedis Treatment Attractiveness Analysis by Distribution Channel, 2022-2032 Figure 127: South Asia Tinea Pedis Treatment Attractiveness Analysis Drug Class, 2022-2032 Figure 128: South Asia Tinea Pedis Treatment Attractiveness Analysis by Country, 2022-2032 Figure 129: India Market Value Proportion Analysis, 2021 Figure 130: India Tinea Pedis Treatment Share Analysis (%), by Disease Indication, 2021 & 2032 Figure 131: India Tinea Pedis Treatment Share Analysis (%), by Route of Administration, 2021 & 2032 Figure 132: India Tinea Pedis Treatment Share Analysis (%), by Distribution Channel, 2021 & 2032 Figure 133: India Tinea Pedis Treatment Share Analysis (%), Drug Class, 2021 & 2032 Figure 134: Thailand Market Value Proportion Analysis, 2021 Figure 135: Thailand Tinea Pedis Treatment Share Analysis (%), by Disease Indication, 2021 & 2032 Figure 136: Thailand Tinea Pedis Treatment Share Analysis (%), by Route of Administration, 2021 & 2032 Figure 137: Thailand Tinea Pedis Treatment Share Analysis (%), by Distribution Channel, 2021 & 2032 Figure 138: Thailand Tinea Pedis Treatment Share Analysis (%), Drug Class, 2021 & 2032 Figure 139: Indonesia Market Value Proportion Analysis, 2021 Figure 140: Indonesia Tinea Pedis Treatment Share Analysis (%), by Disease Indication, 2021 & 2032 Figure 141: Indonesia Tinea Pedis Treatment Share Analysis (%), by Route of Administration, 2021 & 2032 Figure 142: Indonesia Tinea Pedis Treatment Share Analysis (%), by Distribution Channel, 2021 & 2032 Figure 143: Indonesia Tinea Pedis Treatment Share Analysis (%), Drug Class, 2021 & 2032 Figure 144: Malaysia Market Value Proportion Analysis, 2021 Figure 145: Malaysia Tinea Pedis Treatment Share Analysis (%), by Disease Indication, 2021 & 2032 Figure 146: Malaysia Tinea Pedis Treatment Share Analysis (%), by Route of Administration, 2021 & 2032 Figure 147: Malaysia Tinea Pedis Treatment Share Analysis (%), by Distribution Channel, 2021 & 2032 Figure 148: Malaysia Tinea Pedis Treatment Share Analysis (%), Drug Class, 2021 & 2032 Figure 149: East Asia Tinea Pedis Treatment Value Share by Disease Indication 2022 (E) Figure 150: East Asia Tinea Pedis Treatment Value Share by Route of Administration 2022 (E) Figure 151: East Asia Tinea Pedis Treatment Value Share by Distribution Channel 2022 (E) Figure 152: East Asia Tinea Pedis Treatment Value Share Drug Class 2022 (E) Figure 153: East Asia Tinea Pedis Treatment Value Share by Country 2022 (E) Figure 154: East Asia Tinea Pedis Treatment Historical Market Size (US$ Bn) Analysis, 2014–2021 Figure 155: East Asia Tinea Pedis Treatment Current and Future Market Size (US$ Bn), 2021-2032 & Y-o-Y Growth Trend Analysis Figure 156: East Asia Tinea Pedis Treatment Attractiveness Analysis by Disease Indication, 2022-2032 Figure 157: East Asia Tinea Pedis Treatment Attractiveness Analysis by Route of Administration, 2022-2032 Figure 158: East Asia Tinea Pedis Treatment Attractiveness Analysis by Distribution Channel, 2022-2032 Figure 159: East Asia Tinea Pedis Treatment Attractiveness Analysis Drug Class, 2022-2032 Figure 160: East Asia Tinea Pedis Treatment Attractiveness Analysis by Country, 2022-2032 Figure 161: China Market Value Proportion Analysis, 2021 Figure 162: China Tinea Pedis Treatment Share Analysis (%), by Disease Indication, 2021 & 2032 Figure 163: China Tinea Pedis Treatment Share Analysis (%), by Route of Administration, 2021 & 2032 Figure 164: China Tinea Pedis Treatment Share Analysis (%), by Distribution Channel, 2021 & 2032 Figure 165: China Tinea Pedis Treatment Share Analysis (%), Drug Class, 2021 & 2032 Figure 166: Japan Market Value Proportion Analysis, 2021 Figure 167: Japan Tinea Pedis Treatment Share Analysis (%), by Disease Indication, 2021 & 2032 Figure 168: Japan Tinea Pedis Treatment Share Analysis (%), by Route of Administration, 2021 & 2032 Figure 169: Japan Tinea Pedis Treatment Share Analysis (%), by Distribution Channel, 2021 & 2032 Figure 170: Japan Tinea Pedis Treatment Share Analysis (%), Drug Class, 2021 & 2032 Figure 171: South Korea Market Value Proportion Analysis, 2021 Figure 172: South Korea Tinea Pedis Treatment Share Analysis (%), by Disease Indication, 2021 & 2032 Figure 173: South Korea Tinea Pedis Treatment Share Analysis (%), by Route of Administration, 2021 & 2032 Figure 174: South Korea Tinea Pedis Treatment Share Analysis (%), by Distribution Channel, 2021 & 2032 Figure 175: South Korea Tinea Pedis Treatment Share Analysis (%), Drug Class, 2021 & 2032 Figure 176: Oceania Tinea Pedis Treatment Value Share by Disease Indication 2022 (E) Figure 177: Oceania Tinea Pedis Treatment Value Share by Route of Administration 2022 (E) Figure 178: Oceania Tinea Pedis Treatment Value Share by Distribution Channel 2022 (E) Figure 179: Oceania Tinea Pedis Treatment Value Share Drug Class 2022 (E) Figure 180: Oceania Tinea Pedis Treatment Value Share by Country 2022 (E) Figure 181: Oceania Tinea Pedis Treatment Historical Market Size (US$ Bn) Analysis, 2014–2021 Figure 182: Oceania Tinea Pedis Treatment Current and Future Market Size (US$ Bn), 2021-2032 & Y-o-Y Growth Trend Analysis Figure 183: Oceania Tinea Pedis Treatment Attractiveness Analysis by Disease Indication, 2022-2032 Figure 184: Oceania Tinea Pedis Treatment Attractiveness Analysis by Route of Administration, 2022-2032 Figure 185: Oceania Tinea Pedis Treatment Attractiveness Analysis by Distribution Channel, 2022-2032 Figure 186: Oceania Tinea Pedis Treatment Attractiveness Analysis Drug Class, 2022-2032 Figure 187: Oceania Tinea Pedis Treatment Attractiveness Analysis by Country, 2022-2032 Figure 188: Australia Market Value Proportion Analysis, 2021 Figure 189: Australia Tinea Pedis Treatment Share Analysis (%), by Disease Indication, 2021 & 2032 Figure 190: Australia Tinea Pedis Treatment Share Analysis (%), by Route of Administration, 2021 & 2032 Figure 191: Australia Tinea Pedis Treatment Share Analysis (%), by Distribution Channel, 2021 & 2032 Figure 192: Australia Tinea Pedis Treatment Share Analysis (%), Drug Class, 2021 & 2032 Figure 193: New Zealand Market Value Proportion Analysis, 2021 Figure 194: New Zealand Tinea Pedis Treatment Share Analysis (%), by Disease Indication, 2021 & 2032 Figure 195: New Zealand Tinea Pedis Treatment Share Analysis (%), by Route of Administration, 2021 & 2032 Figure 196: New Zealand Tinea Pedis Treatment Share Analysis (%), by Distribution Channel, 2021 & 2032 Figure 197: New Zealand Tinea Pedis Treatment Share Analysis (%), Drug Class, 2021 & 2032 Figure 198: Middle East & Africa Tinea Pedis Treatment Value Share by Disease Indication 2022 (E) Figure 199: Middle East & Africa Tinea Pedis Treatment Value Share by Route of Administration 2022 (E) Figure 200: Middle East & Africa Tinea Pedis Treatment Value Share by Distribution Channel 2022 (E) Figure 201: Middle East & Africa Tinea Pedis Treatment Value Share Drug Class 2022 (E) Figure 202: Middle East & Africa Tinea Pedis Treatment Value Share by Country 2022 (E) Figure 203: Middle East & Africa Tinea Pedis Treatment Historical Market Size (US$ Bn) Analysis, 2014–2021 Figure 204: Middle East & Africa Tinea Pedis Treatment Current and Future Market Size (US$ Bn), 2021-2032 & Y-o-Y Growth Trend Analysis Figure 205: Middle East & Africa Tinea Pedis Treatment Attractiveness Analysis by Disease Indication, 2022-2032 Figure 206: Middle East & Africa Tinea Pedis Treatment Attractiveness Analysis by Route of Administration, 2022-2032 Figure 207: Middle East & Africa Tinea Pedis Treatment Attractiveness Analysis by Distribution Channel, 2022-2032 Figure 208: Middle East & Africa Tinea Pedis Treatment Attractiveness Analysis Drug Class, 2022-2032 Figure 209: Middle East & Africa Tinea Pedis Treatment Attractiveness Analysis by Country, 2022-2032 Figure 210: GCC Countries Market Value Proportion Analysis, 2021 Figure 211: GCC Countries Tinea Pedis Treatment Share Analysis (%), by Disease Indication, 2021 & 2032 Figure 212: GCC Countries Tinea Pedis Treatment Share Analysis (%), by Route of Administration, 2021 & 2032 Figure 213: GCC Countries Tinea Pedis Treatment Share Analysis (%), by Distribution Channel, 2021 & 2032 Figure 214: GCC Countries Tinea Pedis Treatment Share Analysis (%), Drug Class, 2021 & 2032 Figure 215: South Africa Market Value Proportion Analysis, 2021 Figure 216: South Africa Tinea Pedis Treatment Share Analysis (%), by Disease Indication, 2021 & 2032 Figure 217: South Africa Tinea Pedis Treatment Share Analysis (%), by Route of Administration, 2021 & 2032 Figure 218: South Africa Tinea Pedis Treatment Share Analysis (%), by Distribution Channel, 2021 & 2032 Figure 219: South Africa Tinea Pedis Treatment Share Analysis (%), Drug Class, 2021 & 2032 Figure 220: North Africa Market Value Proportion Analysis, 2021 Figure 221: North Africa Tinea Pedis Treatment Share Analysis (%), by Disease Indication, 2021 & 2032 Figure 222: North Africa Tinea Pedis Treatment Share Analysis (%), by Route of Administration, 2021 & 2032 Figure 223: North Africa Tinea Pedis Treatment Share Analysis (%), by Distribution Channel, 2021 & 2032 Figure 224: North Africa Tinea Pedis Treatment Share Analysis (%), Drug Class, 2021 & 2032
Recommendations
Explore Healthcare Insights
View Reports
